New drug cocktail may tame deadly transplant complication
NCT ID NCT05621759
First seen Jan 31, 2026 · Last updated Jun 17, 2026 · Updated 19 times
Summary
This study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells attack the patient's body. The goal is to see if this approach reduces GVHD while causing fewer side effects. Participants will be followed for up to two years after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.